BCL2 and acute myeloid leukemia: Among them is venetoclax (VEN), a selective BCL-2 inhibitor with modest clinical efficacy as a single agent in AML patients, but with a relatively high response rate when combined with hypomethylating agents (HMA; azacitidine or decitabine) or low-dose cytarabine [5,6].